Abstract:Tiechao Jiang, 1– 3 Wenhao Zhang, 1 Zhongyu Wang 1– 3 1 Department of Cardiovascular Medicine, The Third Hospital of Jilin University, Changchun 130033, People's Republic of China; 2 Jilin Provincial Precision Medicine Key Laboratory for Cardiovascular Genetic Diagnosis, China-Japan Union Hospital of Jilin University, Changchun 130033, People's Republic of China; 3 Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, The Third Hospital of Jilin University, Changchun 130033, People's Republic of China Correspondence: Zhongyu Wang Department of Cardiovascular Medicine, The Third Hospital of Jilin University, No. 126, Xiantai Street, Changchun 130033, People's Republic of China Tel +86-431-84995258 Email jldxwzy@jlu.edu.cn Introduction: As a worldwide health issue, the treatment and prevention of atherosclerosis present an important goal. Increased levels of proinflammatory cytokines such as TNF-α-associated chronic inflammatory response cause endothelial cells to lose their ability to regulate vascular function. Lipid-laden immune cells are recruited to the endothelium where they adhere to the endothelial wall and invade the intimal space, thereby leading to the development of atherosclerotic lesions, fatty plaques, and thickening of the arterial wall. In the present study, for the first time, we investigated the effects of laquinimod, an immunomodulatory agent used for the treatment of multiple sclerosis, on human aortic endothelial in a TNF-α-induced atherosclerotic microenvironment. At present, the mechanism of action of laquinimod is not well defined. Methods: The effects of laquinimod on the gene expression of IL-6, MCP-1, VCAM-1, E-selectin, and KLF2 were measured by real-time PCR. ELISA assay was used to determine protein secretion and expression. Phosphorylation of ERK5 and the protein level of KLF2 were measured by Western blot analysis. The attachment of monocytes to endothelial cells was assayed by calcein-AM staining and fluorescent microscopy. Results: Our findings demonstrate that laquinimod reduced the expression of key inflammatory cytokines and chemokines, including IL-6, MCP-1, and HMGB1. We further demonstrate that laquinimod significantly reduced the attachment of monocytes to endothelial cells, which is mediated through reduced expression of the cellular adhesion molecules VCAM-1 and E-selectin. Here, we found that laquinimod could significantly increase the expression of KLF2 through activation of ERK5 signaling. The results of our KLF2 knockdown experiment confirm that the effects of laquinimod observed in vitro are dependent on KLF2 expression. Conclusion: Together, these findings suggest a potential antiatherosclerotic capacity of laquinimod. Further research will elucidate the underlying mechanisms. Keywords: atherosclerosis, laquinimod, endothelial cells, TNF-α, VCAM-1, E-selectin, KLF2

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation

Laquinimod (ABR-215062) Suppresses the Development of Experimental Autoimmune Encephalomyelitis, Modulates the Th1/Th2 Balance and Induces the Th3 Cytokine TGF-β in Lewis Rats

Laquinimod exerts anti-inflammatory and antiapoptotic effects in retinal ischemia/reperfusion injury

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea

Laquinimod Protects Against TNF-α-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2

Laquinimod attenuates oxidative stress-induced mitochondrial injury and alleviates intervertebral disc degeneration by inhibiting the NF-κB signaling pathway

Depletion of Microglia with PLX3397 Attenuates MK-801-induced Hyperactivity Associated with Regulating Inflammation-Related Genes in the Brain

Laquinimod Ameliorates Spontaneous Colitis in Interleukin-10-gene-deficient Mice with Improved Barrier Function

Delayed microglial depletion after spinal cord injury reduces chronic inflammation and neurodegeneration in the brain and improves neurological recovery in male mice

Isoliquiritigenin alleviates experimental autoimmune encephalomyelitis by modulating inflammatory and neuroprotective reactive astrocytes

Novel recombinant protein flagellin A N/C attenuates experimental autoimmune encephalomyelitis by suppressing the ROS/NF-κB/NLRP3 signaling pathway

18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination

Quercetin hinders microglial activation to alleviate neurotoxicity via the interplay between NLRP3 inflammasome and mitophagy

A Novel Quinolyl-Substituted Analogue of Resveratrol Inhibits LPS-Induced Inflammatory Responses in Microglial Cells by Blocking the NF-κB/MAPK Signaling Pathways

Senolytic treatment depletes microglia and decreases severity of experimental autoimmune encephalomyelitis

Protecting effect of emodin in experimental autoimmune encephalomyelitis mice by inhibiting microglia activation and inflammation via Myd88/PI3K/Akt/NF-κB signalling pathway

Quinolinic Acid Toxicity on Oligodendroglial Cells: Relevance for Multiple Sclerosis and Therapeutic Strategies

A novel combination approach to effectively reduce inflammation and neurodegeneration in multiple sclerosis models

Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model

Activation of Murine Microglial N9 Cells is Attenuated Through Cannabinoid Receptor CB2 Signaling

Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in an Experimental Autoimmune Encephalomyelitis Mouse Model